anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study have only one arm that is anti-CTLA-4/PD-1 expressing EGFR-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing EGFR-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
Patients participate in interviews over 20-40 minutes and undergo collection of hair samples at baseline and 18-24 months. Patients' medical records are also reviewed.
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with recurrent/metastatic head and neck cancers. At least 30 subjects will be recruited in this study. The subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2 by an intravenous infusion (IV), every 21 days (q3w, 1 cycle). All patients will receive the treatment until disease progression, intolerable toxic reaction, death, or withdrawa by investigator or patient decision (a maximum of 8 cycles). Delays in drug administration is allowed from the cycle 2, however, the delays should be no more than 3 weeks. Dose adjustments after the cycle 2 is permitted, and the minimum dose is 12mg/m2.
PURPOSE: To provide the molding which is prepd. by incorporating the concd. extracts of Chinese herb medicines having the respective characteristics based on Botany at specific ratios into the molding, is formed without using food additives, synthetic flavoring agents, etc., at all, has the specific taste and aroma and has the ample refreshing feel and palatability to be liked by anyone. CONSTITUTION: This molding is prepd. by compounding (A) 50 to 90(wt.)% concd. extracts consisting of one or >=2 kinds of the Chinese herb medicine materials (e.g. Pueraria, etc.) effectual for eliminating and preventing a thirst, (B) 2 to 30% concd. extracts consisting of one or >=2 kinds of the Chinese herb medicine materials (e.g. cinnamon, etc.) having stomachic, cordial and tonic effects, (C) 0.3 to 3% concd. extracts consisting of one or >=2 kinds of the Chinese herb medicine materials (e.g. licorice, etc.) effectual for neutralizing and relieving the toxicity of the drugs of the Chinese herb medicines or food and drink, (D) 5 to 20% water solubility accelerating and sweeting agents for the Chinese herb medicine material extracts and (E) 5 to 30% distilled water in which 10 to 30% caramel is dissolved and incorporated.  The molding contributes to the maintenance of health by the medical effect of the herb medicine materials.
A composition for activation of beta-endorphin comprising the extract of Opuntia ficus-indica var. saboten is provided to promote expression of beta-endorphin in hypothalamus or pituitary gland, thereby preventing disease caused by a lowering of inherent immunity, a lowering of immunity caused by chronic disease or chronic stresses. A composition for activation of beta-endorphin comprises the extract of Opuntia ficus-indica var. saboten which is prepared with water, alcohol selected from methanol, ethanol, propanol and butanol or alcohol solution, wherein the Opuntia ficus-indica var. saboten is a fruit of Opuntia ficus-indica var. saboten. The daily dosage of the Opuntia ficus-indica var. saboten extract is 1-2 g/kg, preferably 1.3-1.8 g/kg.
Fresh frozen plasma is used very frequently in the US. Many plasma transfusions are given prior to a procedure in order to correct perceived bleeding risk, yet there is little evidence to support that use of plasma reduces bleeding. There has never been an adequately powered trial to establish the efficacy of plasma and document the risks. This pilot study will evaluate the feasibility of conducting a research protocol that will lead to a large scale clinical trial designed to evaluate the treatment effectiveness of prophylactic plasma transfusion in patients with moderately elevated INRs prior to undergoing an invasive procedure outside of the operating room.

Study subjects will be randomly allocated to either receive either plasma transfusion prior to the procedure, or to no treatment. Study outcomes will be compared between the two study arms. Recruitment rates, protocol adherence, and rates of study outcomes will be assessed to determine the feasibility of the large scale trial.
Unopened vials of Busulfan Injection must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F). ). Discard unused portion.

Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP is stable at room temperature (25°C) for up to 8 hours but the infusion must be completed within that time.

Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP is stable at refrigerated conditions (2°C to 8°C) for up to 12 hours but the infusion must be completed within that time.

Busulfan Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures 1.
Ketorolac and its metabolites are eliminated primarily by the kidneys. Patients with reduced creatinine clearance will have diminished clearance of the drug [see Clinical Pharmacology (12.4)]. SPRIX is contraindicated in patients with advanced renal impairment [see Contraindications (4)].

In patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and renal blood flow, which may precipitate overt renal decompensation. Decreased intravascular volume such as when oral intake is poor increases the risks of renal toxicity with NSAIDs. Therefore, patients treated with SPRIX should be adequately hydrated. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. 

Use SPRIX with caution in patients with impaired renal function, heart failure, liver dysfunction, those taking diuretics or ACE inhibitors, and the elderly. Assess the risks and benefits prior to giving SPRIX to these patients, and follow these patients closely during SPRIX therapy. Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury such as interstitial nephritis and nephrotic syndrome.
Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care. TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment. Patients who do not attend the initial visit will be rescheduled. After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.
General anesthesia can inhibit sympathetic nerve activity and attenuate stress response, but it also inhibits vagus nerve activity. The decrease of vagus nerve activity can cause cardiovascular complications, especially ventricular arrhythmia in patients with coronary heart disease. Some study have shown that electrical stimulation of transcutaneous acupoints can regulate the function of autonomic nervous system and enhance the activity of vagus nerve so as to protect myocardial tissue. But the effect on autonomic nervous function and myocardial injury markers in elderly patients with coronary heart disease was not reported. Heart rate variability (HRV) is a noninvasive and reliable index reflecting cardiac autonomic nervous function. High-sensitive cardiac troponin hs-cTnT is the best myocardial injury marker.

The investigators plan to recruite 150 patients with coronary heart disease of both sexes, aged 65-80 yr, undergoing elective lumbar decompression and fusion internal fixation surgery. They will be randomly divided into 2 groups(n=75 each)using random number table : control group ( group C ) and TAES group (group T). Patients in group T receive TEAS (disperse-dense waves, frequency 4/20Hz) at the points of PC6 (Neiguan) and PC4 (Ximen) from 30 min before anesthesia induction to the end of surgery, the optimal intensity will be adjusted to maintain a slight twitching of the midfinger or ring finger (De-Qi response). Patients in group C receive electrode plate at the same acupoints without any electrical stimulation. Heart rate variability will be collected on 1 day before surgery, 1, 3 and 5d after surgery. 3mL of venous blood will be collected before the induction of anesthesia, 1, 3 and 5d after surgery, the serum will be isolated for the measurement of serum concentration of high-sensitive troponin T (hs-cTnT)、CK、CRP.
Participants will undergo apheresis to collect cells to make SLAMF7 fresh peripheral blood mononuclear cells (FPBMC). These cells will be activated in the lab to fight against multiple myeloma. About 3-4 days after apheresis, participants will start receiving infusions of SLAMF7 FPBMC. Throughout treatment, participants will have blood taken for labs, to check disease status and also to look at immune response. Study treatment will stop if the participant has disease progression.
Severe cases of SARS-CoV-2 infection have shown an inflammatory neutrophil and mucus-mediated airway exclusion pathway similar to previously described acute respiratory distress syndrome (ARDS) in other viral syndromes (Narasaraju et al., Am J Pathol. 2011). Lung neutrophilia in ARDS is related to significant neutrophil extracellular trap (NET) production and formation. Thus, NET production is likely contributing to the severe lung pathology in SARS-CoV-2 (Yu Zuo et al. Journal of Clinical Investigation Insight. 2020). Recent connections have been made between NET formation in SARS-CoV-2 patients and excessive thrombosis and the development of cytokine storm further warranting evaluation as a potential site for consideration of treatment (Barnes, Betsy et al. J exp Med. 2020). Dornase alfa (Pulmozyme) is a recombinant human deoxyribonuclease I, that acts as a mucolytic by cleaving extracellular chromosomal DNA from NETs and other cell-free DNA. Unknown are the effects of dornase alfa therapy on SARS-CoV-2 related ARDS and if therapy with dornase alfa truly reduces the amount of NETs in the severely damaged lungs.

This study is a non-randomized, single-center, open-label clinical trial to evaluate the potential benefit and cellular mechanism of nebulized dornase alfa administration in mechanically ventilated patients with SARS-CoV-2 related ARDS. Evaluation of dornase alfa effects at a cellular level will be measured by analysis of blood samples before and after the 3 days of therapy for cell-free DNA, quantification of citrullinated histone H3, quantification of Myeloperoxidase-DNA complexes and analysis of bronchoalveolar lavage samples for quantification of NETs and cell count and differential.
Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If there is a dominant follicle (almost 12 × 12 mm in diameter), endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before ovulation. If there isn't dominant follicle and intramuscular human menopausal gonadotropin at a dose of 75-150 IU was administered each day after day 12 if there follicle development was poor. The embryo transfer day is decided according embryo development.
Patients who were diagnosed according to the criteria as being critically ill by the ED responsible physician (patients whose basic vital functions are unstable, who receive supportive treatment or whose general condition is expected to deteriorate) were included. Patients over 18 years of age who agreed to participate in the study were included after consent was obtained from the patient or their relatives. Patients who did not meet the definition of critical patients, whose follow-up was incomplete, who did not want to participate in the study, pregnant women, and patients under 18 years of age were all excluded. A healthy control group was formed from the relatives of the patients who came to the ED outpatient clinics, as well as hospital staff who wanted to participate in the study.

Age, gender, known diseases, medications, vital parameters, and the laboratory results from critically ill patients and healthy volunteers admitted to the ED were recorded, and blood samples taken for D-Lactate and SCUBE-1 at the time of admission to the emergency room were placed in Ethylenediaminetetraacetic acid (EDTA) tubes. Clinical scores, such as the Glasgow Coma Scale (GCS), Acute Physiology and Chronic Health Evaluation (APACHE) II, Revised Trauma Score (RTS), and shock index were calculated. Critical patients were divided into the following seven groups according to their emergency department diagnosis: central nervous system, cardiovascular system, respiratory system, gastrointestinal system/metabolic, sepsis, trauma, and other. The clinical outcomes of these patients (ED length of stay, ICU or ward admission, ED and ICU mortality) were also noted. The relationship between the patient's clinical scoring (GCS, APACHE II, RTS and shock index ), laboratory results, and mortality status with D-Lactate and SCUBE-1 levels was compared. At the same time, the diagnostic value of d-lactate and SCUBE-1 for distinguishing critically ill patients was investigated.
PURPOSE: A pharmaceutical composition containing niacin is provided to reduce release of pro-inflammatory cytokine and to suppress NF-kappa B signal transduction. CONSTITUTION: A pharmaceutical composition for treating sepsis or septic shock contains 10-40 wt% of as an active ingredient. The dose of the niacin is 30mg/kg-120mg/kg. The composition further contains a carrier, excipient, or diluent. The composition is alternatively used with anti-inflammatory agent, anticoagulants, antibiotics, or anti-allergic agent. The pharmaceutical composition is administered by oral, intravenous, intramuscular, or subcutaneous injection.
PURPOSE OF REVIEW: The infrapatellar branch of the saphenous nerve (IPS) is an under-investigated nerve that can be a source of chronic knee pain. This literature review aims to deliver an up-to-date review of chronic pain transmitted via the IPS along with therapeutic approaches available for pain refractory to conservative measures.
RECENT FINDINGS: Knee pain transmitted via the IPS can arise from several etiologies. Damage to the IPS is often iatrogenic and develops following total knee arthroplasty, anterior cruciate ligament reconstruction, and other knee surgical procedures. Other causes of IPS-derived pain include entrapment of the nerve, neuromas, Schwannomas, and pain from knee osteoarthritis transmitted through the IPS.This article investigated therapeutic approaches to pain derived from the IPS. Common approaches included radiofrequency ablation, neuroma excisions, Schwannoma excision, nerve blocks, surgical exploration, surgical release of an entrapped nerve, cryoablation, and peripheral nerve stimulation. Pain scores, duration of pain relief, adverse events, and secondary outcomes were all included in this review. A subset of the patient population experiences chronic pain deriving from the IPS that is refractory to conservative treatment measures. This review aims to evaluate the etiologies and therapeutic approaches for chronic pain arising from the IPS refractory to conservative treatments.
This control will involve glasses that selectively filter short wavelength (e.g., ultraviolet), but not visible blue light during the same time window. Participants will wear these glasses while awake from 6 p.m. to 8 a.m.
<P>PROBLEM TO BE SOLVED: To provide an anti-allergic composition comprising a plant of the genus Rosa of the family Rosaceae and an ingredient derived from the plant and α-cyclodextrin and to provide a food and drink and an additive for the food and drink comprising the composition.  <P>SOLUTION: The anti-allergic composition comprises (1) an extract from the plant of the genus Rosa of the family Rosaceae, (2) the plant of the genus Rosa of the family Rosaceae and (3) at least one kind of the extract from the plant of the genus Rosa of the family Rosaceae and/or a fermented material obtained by fermenting and culturing the plant of the genus Rosa of the family Rosaceae and the α-cyclodextrin. The food and drink comprises the anti-allergic composition. The additive for the food and drink comprises the anti-allergic composition. The anti-allergic composition, etc., inhibit and ameliorate allergic diseases and can continuously be used over a long period without causing adverse effects, etc., peculiar to medicines.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Sepsis is a common, heterogeneous, and frequently lethal condition of organ dysfunction and immune dysregulation due to infection. The causes of its heterogeneity, including the contribution of the pathogen, remain unknown. Using cecal slurry, a widely used murine model of intraperitoneal polymicrobial sepsis, as well as 16S ribosomal RNA sequencing and measurement of immune markers, we performed a series of translational analyses to determine whether microbial variation in cecal slurry composition (representing intra-abdominal pathogens) mediated variation in septic response. We found wide variation in cecal slurry community composition that changed markedly over the 24-h course of infection. This variation in cecal slurry bacteria led to large variation in physiologic and inflammatory responses. Severity of inflammatory response was positively correlated with intraperitoneal enrichment with Enterobacteriaceae. Likewise, in a human cohort of patients with intra-abdominal abscesses, Enterobacteriaceae was also associated with increased inflammatory markers. Taken together, these data demonstrate that intra-abdominal Enterobacteriaceae drives inflammation in sepsis both in animal models and human subjects. More broadly, our results demonstrate that pathogen identity is a major driver of the host response in polymicrobial sepsis and should not be overlooked as a major source of phenotypic heterogeneity.
Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
The invention discloses a traditional Chinese medicine decoction used for treating epigastric pain. The decoction is prepared from following raw materials in parts by weight: 10-15 of dandelion, 8-14 of sargentgloryvine stem, 10-15 of root of herbaceous peony, 6-12 of nutgrass galingale rhizome, 5-10 of cape jasmine fruit, 10-15 of lindera aggregate, 7-13 of lily, 5-10 of licorice, 12-16 of moutan bark, 4-8 of Chinese goldthread, 14-18 of flower of common jasmine, 10-15 of finger citron, 16-22 of corydalis tuber, 20-25 of Chinese hawthorn root, 12-18 of bitter orange, 15-20 of dried ginger, 10-15 of bunge pricklyash leaf, 5-10 of atractylodes macrocephala, 18-24 of radix codonopsitis, 15-20 of poria cocos, 10-15 of costus root and 5-10 of lilyturf root. The traditional Chinese medicine decoction has functions of clearing away heat and toxic materials, tonifying spleen, supplementing qi, warming the middle, invigorating the spleen, promoting qi circulation, relieving pain, relieve depression of the liver-qi, and promoting blood circulation to dispel blood stasis. The decoction can effectively treat and cure the epigastric pain, and has good curative effects for gastric ulcer, duodenal ulcer, atrophic gastritis, superficial gastritis, and other gastric diseases. No recrudescence occurs after patients are cured. The decoction is free of toxic and side effects for human bodies and is entirely reliable.
A herbal compsn. to promote the treatment of genetic mucoviscidosis contains cpds. of natural origin, namely: 100-120g rape honey, 20g propolis, 20 g.s of each of: extracts of elder, lime blossoms, acacia and powdered blood-wort, cowslip-root wormwood, mulberry leaves and cinnamon, and of pounded garlic. These ingredients are suited with 100 mls of 30-70% ethanol, and having stood for 24 hours, are pressed out. The pressings are united with the plant extracts to prepare tinctures, 2 g-s of wheat germ are added to the honey in finely powdered form and liquidised. Liquidising is finished when the mixed tinctures are also added.
Signs And Symptoms

There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated.

Oral LD50: The acute oral LD 50 of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats. 

Dialysis: Dialysis data are not available for lactulose. Its molecular similarity to sucrose, however, would suggest that it should be dialyzable.
Methods and systems for predicting adherence to Multiple Sclerosis treatment are described. In one embodiment, a member undergoing a Multiple Sclerosis treatment is identified. Member data associated with the member undergoing the Multiple Sclerosis treatment is accessed. Pre-prediction time period adherence data associated with the member, member prescription data associated with the member, member family data associated with the member, and member demographic data associated with the member are determined based on the member data associated with the member. A likelihood that the member will be adherent to the Multiple Sclerosis treatment over a prediction time period is determined based on the pre-prediction time period adherence data, member prescription data, member family data, and member demographic data. Other methods and systems are described.
As a major oncology and hepatology center, the investigators perform about 3-5 guided biopsies for liver tumors weekly. Ultrasound is the preferred modality for imaging biopsies due to its ability to visualize and position the biopsy needle in real time with high accuracy and safety, is nonionizing, and is quicker compared to other techniques, especially CT-guided biopsies. The failure rate of ultrasound guided liver biopsies (including cases where biopsy was declined to be performed due to lack of lesion visibility) is about 10%. By comparison, in the investigators' practice genotyping of metastatic tumors, with multiple core biopsies, is often requested for entry into oncology trials, and failure of tumor genotyping after biopsy is estimated to be about 30%.

Recently, the first ultrasound contrast agent was FDA-approved for characterization of liver lesions \[sulfur hexafluoride lipid-type A microspheres (Lumason, Bracco Diagnostics, Monroe Township, NJ)\]. The microbubble agent is deemed safe, including in cardiac failure patients and those with chronic airway obstruction. Injecting microbubbles may allow better visualization of lesions and adjacent vasculature by enhancing the microvasculature and adjacent vessels and potentially reduce incidence of failed biopsy or bleeding complications. In addition, determination of necrotic regions in a lesion may allow better direction of biopsy.

Yet there is limited literature on the use of ultrasound contrast agents for improving targeted liver biopsies. The investigators intend to prospectively assess the non-diagnostic biopsy and complication rates in a group of patients who undergo contrast-enhanced ultrasonography (CEUS) using microbubbles at the time of biopsy. The investigators will then compare the results from this group with the failure and complication rate from a control group of patients undergoing the standard US-guided biopsy procedure. Over 12 months the investigators expect to perform approximately 200 biopsies. Power analysis suggests that 125 patients in both contrast-enhanced sonography and control groups, each, are required. The investigators should be able to enroll sufficient patients in 18 months